European Medicines Agency Validates Hengrui's Application for Prostate Cancer Drug Wevdury

01:17 AM EDT, 10/09/2026 (MT Newswires) -- European Medicines Agency validated Hengrui Pharma's application for Wevdury, or fuzuloparib, plus abiraterone acetate and prednisone or prednisolone as a treatment for metastatic castration-resistant prostate cancer in adults. The pharmaceutical company said Thursday that it supported its marketing authorization application for the treatment with data from the phase 3 SHR3162-III-305 study.